Mayo Clinic Laboratories > Oncology > Colorectal & GI > Next-generation sequencing panel

Next-generation sequencing

Guiding treatment and improving outcomes for more patients

Because of the potential for increased medication toxicity and costs related to treatment of colorectal cancer (CRC), identifying individuals most likely to respond to targeted therapies is essential for appropriate patient management. We offer comprehensive next-generation sequencing to identify genetic variations associated with therapeutic outcomes. We also offer microsatellite instability (MSI) testing and mismatch repair (MMR) analysis to assess how likely patients are to benefit from certain treatment options.  

NEXT-GENERATION SEQUENCING TEST MENU

Next-generation sequencing Next-generation sequencing
Anti-PD-L1 immunotherapy Anti-PD-L1 immunotherapy

Next-generation sequencing

While monoclonal antibodies against EGFR, such as cetuximab and panitumumab, can block the growth and spread of colorectal cancer, studies have shown that tumors with specific gene mutations will not respond to these therapies. Based on internal Mayo Clinic data, Mayo Clinic Laboratories’ expanded genetic panel identified 24% more patients who are unlikely to benefit from EGFR-targeted therapy. Our next-generation sequencing panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.

Key testing

Advantages

  • Enables insights on diagnosis, prognosis, and treatment response by sequencing APC, BRAF, HRAS, KRAS, MLH1, MSH2, MSH6, NRAS, and PMS2.
  • Provides MSI status.

Advantages

  • Offers cell-free DNA testing on peripheral blood when tumor testing is not available for CRC patients.
  • Detects the presence of common KRAS mutations at codons 12, 13, 61, and 146.
View the chart 24% of additional patients identified through our extended RAS/RAF testing who are unlikely to benefit from EGRF-targeted therapy.

Highlights

Colorectal panel provides detailed cancer information

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Learn more

Anti-PD-L1 immunotherapy

Anti-PD-L1 immunotherapies such as pembrolizumab have recently emerged as a therapeutic option in CRC. These therapies are designed to block the PD-L1/PD-1 immune checkpoint pathway, thereby assisting the immune system in tumor cell detection. However, current data indicates that only patients with defective MMR and/or high MSI are likely to benefit from this therapy. Our rapid tumor microsatellite instability (TMSI) evaluation is the only clinically available assay of its kind to offer fast test results.

Key testing

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.